<DOC>
	<DOCNO>NCT00029627</DOCNO>
	<brief_summary>The purpose study investigate role brain receptor call alpha2-adrenoreceptors regulate sympathetic nervous system , maintain supply blood fuel body 's organ time stress , fear , anger , exercise . Alpha ( 2 ) -adrenergic receptor ( alpha ( 2 ) -AR ) play role variety physiological function . There three subtypes alpha ( 2 ) -ARs , difference unknown . This study examine functional role three subtypes compare behavioral , biochemical , psychophysiological , autonomic function effect alpha ( 2 ) -AR drug clonidine yohimbine . Participants study undergo physical examination , electrocardiogram ( ECG ) , blood , urine , saliva test . Women hormone test determine time last period time next ovulation . Participants undergo neuropsychological testing procedure .</brief_summary>
	<brief_title>Brain Receptors Sympathetic Nervous System Regulation</brief_title>
	<detailed_description>Alpha ( 2 ) -adrenergic receptor ( alpha ( 2 ) -AR ) cell surface receptor catecholamines bind G ( ) /G ( 0 ) family G proteins . Alpha ( 2 ) -ARs widely distribute central peripheral nervous system , know play important role regulation catecholamine release . This mechanism broad distribution receptor explain role wide variety physiological function . Alpha ( 2 ) -AR mediate central hypotensive , sedative , anesthetic , analgesic response alpha ( 2 ) -AR agonist . However , cardiovascular response alpha ( 2 ) -AR agonist subject interindividual variation human population . Such variability may explain genetic variation structure receptor , cognate G proteins , transductional effector , downstream intracellular target . Molecular pharmacological research define three alpha ( 2 ) -ARs subtypes designate alpha ( 2 ) ( A ) , alpha ( 2 ) ( B ) , alpha ( 2 ) ( C ) . All three alpha ( 2 ) -AR subtypes involve regulation blood pressure , receptor also modulate sedation , analgesia , regulation insulin release , renal function , cognition behavior . Biochemical research identify three human gene uniquely encode alpha ( 2 ) -ARs . Recently , preclinical study polymorphisms three alpha ( 2 ) -AR subtypes describe . The three polymorphism relatively abundant , two appear functional vitro . However , human vivo physiological effect polymorphism unknown . This study elucidate potential functional role three alpha ( 2 ) -AR subtypes human compare behavioral , biochemical , psychophysiological , autonomic function effect well-established alpha ( 2 ) -AR agonist antagonist , clonidine yohimbine , respectively , individual select particular alpha ( 2 ) -AR genotype . Based preclinical study follow hypothesis test : 1 ) subject homozygous heterozygous alpha ( 2 ) ( A ) -AR Asn251Lys substitution show potentiation clonidine-induced effect , relative subject Asn251/Asn251 genotype , reduction yohimbine-induced effect , 2 ) subject homozygous heterozygous alpha ( 2 ) ( B ) -AR three glutamic acid deletion ( residues 301-303 ) show reduced effect alpha ( 2 ) -AR agonist clonidine possibly potentiation effect yohimbine , 3 ) evaluate whether altered response either direction occur subject homozygous heterozygous in-frame deletion alpha ( 2 ) ( C ) -AR homologous repeat occur codon 322-325 relative subject without deletion allele .</detailed_description>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>INCLUSION CRITERIA Healthy subject negative firstdegree family history psychiatric disorder determine Family Interview Genetic Studies eligible . Subjects must willing participate challenge study . Subjects must good physical health . Subjects must absence Axis I Axis II DSMIV diagnosis . Subjects exclude evidence axis I psychiatric disorder presence axis II personality disorder . Smokers ineligible participate . Subjects recent life stressor ( 3 month ) chronic life stressor ( 1 year ) ineligible . Subjects must age 18 50 . Subjects must meet criterion one 6 genotypically define subgroup . Subjects must take antidepressant medication likely alter monoamine neurochemistry cerebrovascular cardiovascular function least 6 month prior challenge study . EXCLUSION CRITERIA Subjects exclude medical neurological illness likely affect physiology anatomy , i.e . hypertension , cardiovascular disorder . Subjects must history drug ( include BZDs ) alcohol abuse within 1 year lifetime history alcohol drug dependence . Subjects current previous regular use ( great 4 week ) BZDs excessive use alcohol ( great 8 ounces/week men great 6 ounces/week woman ) past present ineligible participate . Women currently pregnant breastfeed eligible . Subjects hear 40 dB ( HL ) pure tone 1000 4000 Hz span ( Welsh Allen audioscope ) exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>Alpha2-Adrenoreceptors</keyword>
	<keyword>Polymorphisms</keyword>
	<keyword>Challenge Study</keyword>
	<keyword>Yohimbine</keyword>
	<keyword>Clonidine</keyword>
	<keyword>Subtypes</keyword>
	<keyword>Normal Control</keyword>
	<keyword>HV</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>